Navigation Links
Advanced Life Sciences Announces Fourth Quarter and Full Year 2007 Financial Results
Date:2/19/2008

2006.

2007 Achievements

-- Completed and reported positive results from Trial CL-07, a thorough

QT study for cethromycin which showed that cethromycin had no effect

on QT changes, supporting its favorable cardiac safety profile;

-- Completed private placement financing with existing and new

shareholders which added net proceeds of $18 million in cash to the

balance sheet;

-- Progressed negotiations with multiple prospective partners regarding

the commercial development of cethromycin as a treatment for CAP;

-- Completed clinical development and released positive efficacy and

safety data from two pivotal Phase III clinical trials that enrolled

over 1,100 patients from over 200 clinical sites worldwide for the use

of cethromycin to treat CAP;

-- Engaged an outside contract research organization to complete medical

writing activities and conversion of the NDA database into electronic

filing format;

-- Completed API and drug product manufacturing and initiated stability

testing to support the CMC requirements for the cethromycin NDA

submission;

-- Completed microbiology surveillance studies necessary for the

cethromycin NDA submission;

-- Completed efficacy study in which cethromycin was shown to be

100% protective in preventing inhalation anthrax in non-human

primates;

-- Granted Orphan Drug Designation by the FDA for the use of cethromycin

in the prophylactic treatment of patients exposed to inhalation

anthrax;

-- Presented 11 posters on cethromycin at The American Society for

Microbiology's 47th Annual Interscience Conference on Antimicrobial

Agents and Chemotherapy (ICAAC) in Chicago and the 45th Annual Meeting

of the Infectious Disease Society of America (IDSA) in San Diego;

-- Forme
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
3. Advanced Cell Technology Announces Proposed Financing
4. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference
7. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
8. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
9. Advanced Bionics Deploys CEVA-TeakLite(TM) DSP Core to Enhance Its Harmony(TM) HiResolution(R) Bionic Ear System
10. NIH Announces Advanced Cell Technologys Single Cell Embryo Biopsy Technique as a Means to Derive Embryonic Stem Cells to be Considered for Federal Funding
11. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... October 20, 2014 Convey Computer ... a team from Iowa State University won first place ... Using a Convey HC-2ex, the team’s solution achieved the ... faster than the second place finisher. , Experts from ... upon the month long challenge, using a variety of ...
(Date:10/20/2014)... , Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... million which brings Q3 orders to $5.8 million and provides a ... projects in North America and one in ... to bid new projects at record levels," said Peter Bruijns ... higher at the end of Q3 than they have been for ...
(Date:10/20/2014)... GAITHERSBURG, Md. , Oct. 20, 2014  GenVec, Inc. ... Zola P. Horovitz , Ph.D., from its board of ... GenVec board in August 2003, and served as its chairman ... also served on the Nominating and Corporate Governance and Audit ... Zola for more than a decade of dedicated service to ...
(Date:10/20/2014)... 20, 2014 OncLive® ... Cancer Center at Thomas Jefferson University has joined ... the Strategic Alliance Partnership program, the Sidney Kimmel ... to raise awareness of the Center’s cutting-edge research ... projects. Clinicians and other health care professionals from ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... ICLL) today announced that the Australian Therapeutic Goods,Administration ... to,prevent Japanese Encephalitis. This final decision step for ... Australian Drug Evaluation,Committee (ADEC) in December 2008. , ... Australian authorities represents the first,regulatory approval for the ...
... Aerolase Corporation, a leading manufacturer of next-generation portable ... sales increased dramatically in 2008 over 2007. The ... market helped to more than offset current economic ... record sales month for Aerolase, and 2008 overall ...
... Jan. 23 Peter T. Wilderotter, president and CEO ... following statement today in response to FDA clearance of ... is an exciting first step for Geron and for ... to advances in medical research. There has been so ...
Cached Biology Technology:Australian Authorities (TGA) First to Grant Final Product Approval for Intercell's Vaccine to Prevent Japanese Encephalitis 2Australian Authorities (TGA) First to Grant Final Product Approval for Intercell's Vaccine to Prevent Japanese Encephalitis 3Australian Authorities (TGA) First to Grant Final Product Approval for Intercell's Vaccine to Prevent Japanese Encephalitis 4Aerolase Reports Strong Sales in 2008 for Portable Aesthetic Lasers 2Aerolase Reports Strong Sales in 2008 for Portable Aesthetic Lasers 3Christopher and Dana Reeve Foundation Response to FDA Clearance of Geron's Clinical Trial 2
(Date:10/22/2014)... JOSE, Calif. , Oct. 20, 2014 ... the United States Air Force Research Laboratory (AFRL), has ... Integrative Medicine (AzCIM) at the University of Arizona College ... receive research funding.  The AzCIM project,s goal is to ... ability to collect different volumes of sweat under a ...
(Date:10/22/2014)... Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its third quarter ended September 30, 2014. Revenue ... increase of 40% compared to $4.3 million in the same ... 2014 was $4.1 million compared to $1.0 million in the ... three month period was primarily due to: i) a $1.0 ...
(Date:10/18/2014)... stress-related psychiatric disorders are associated with increased ... mechanisms underlying this relation are unknown. Understanding ... of targeted preventive strategies and new or ... work is presented at the European College ... international group of researchers from Germany and ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 3Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7Researchers find why depression and aging linked to increased disease risk 2
... drop in public concern over global warming, Americansregardless of political ... to the results of a national survey released today by ... survey found support for: , Funding more research ... percent) Tax rebates for people buying fuel-efficient vehicles ...
... , BLUE BELL, Pa. , Feb. ... announced that its Mexican subsidiary has been awarded a contract ... of Internal Affairs/National Citizen Registry) to create and manage an ... create a database with iris, fingerprint and facial biometric data ...
... available in <A HREF=",http://chinese.eurekalert.org/zh/pub_releases/2010-02/sfeb-cbc020310.php,">Chinese . ... do Paran and Instituto Carlos Chagas have ... expanded CD133+ cells human umbilical cord blood ... injecting them into a rat model. Patients ...
Cached Biology News:According to new survey, Americans support strong climate, energy policies 2Unisys Awarded Contract to Provide Advanced Biometric Citizen Identification Solution to Government of Mexico 2Unisys Awarded Contract to Provide Advanced Biometric Citizen Identification Solution to Government of Mexico 3
... for the fast and simple integration of ... position (for the generation of transgenic mouse ... to allow neomycin / kanamycin selection in ... prokaryotic promoter (gb2) for expression of kanamycin ...
Includes a choice of any 3 EasySep mouse selection kits and EasySep magnet...
... These 1.5L PYREX trypsinizing flasks ... tissue samples into cell suspensions ... Heavy beaded neck accepts cotton ... vigorous agitation. • Height of ...
... Application: For the efficient enrichment ... mammalian tissue or cell culture. The ... synthesis, degradation and metabolic pathway analysis. ... acetyltransferase deficiency in children, cystic fibrosis ...
Biology Products: